Emmes CRO acquires Orphan Reach

By The Science Advisory Board staff writers

May 14, 2021 -- Clinical Research Organization (CRO) Emmes, a portfolio company of Behrman Capital, announced it has acquired Orphan Reach, an organization specialized in clinical research related to rare diseases.

This marks Emmes' second acquisition since Behrman's investment in 2019 and builds on its recent acquisition of Neox S.R.O. in December 2020, the company stated in a release. Orphan Reach was founded about 20 years ago and has offices in Ireland, Germany, India, Canada, and the U.S.

Financial terms of the transaction were not disclosed.

Copyright © 2021 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter